Benzodiazepine Bridging for Anxious-Distress MDD
A short benzodiazepine bridge could cover the weeks before his SSRI takes effect on severe anxious distress — his father's alcohol use disorder is exactly the kind of family history that makes that bridge a genuine dependence risk, not just a convenience.
B.K., a 33-year-old software developer, presents with a new depressive episode marked by prominent anxious distress — a PHQ-9 of 21 alongside a GAD-7 of 18, with symptoms he describes as a constant sense that something terrible is about to happen, restlessness that keeps him pacing his apartment at night, and sleep so disrupted he has taken a leave of absence from work over the past ten days. This is his first depressive episode, and he has no other chronic illness.
He has no personal history of substance use of any kind — no alcohol, no recreational drug use, nothing flagged on a careful screening interview. Suicide risk was assessed directly rather than inferred from the PHQ-9 total: item 9 reads zero, he denies any thought of self-harm, and he has no plan, intent, or access concern — which matters before dispensing any CNS depressant, and matters more here because anxious distress is itself associated with elevated suicide risk in major depression. His father, however, has a documented history of alcohol use disorder, including two treatment attempts in B.K.'s twenties that B.K. remembers clearly and describes as having shaped how carefully he thinks about anything with dependence potential in his own life.
Sertraline is being started for the depression, but SSRIs typically take two to four weeks to meaningfully reduce anxious symptoms, and B.K.'s current distress is severe enough to have already cost him his ability to work. A short-term benzodiazepine bridge — a defined, time-limited course to cover the gap until the SSRI takes effect — is a well-established practice for exactly this kind of severe anxious-distress presentation, though benzodiazepines carry their own class boxed warning covering abuse, dependence, and withdrawal. The complication is that benzodiazepine dependence risk is meaningfully elevated by a first-degree family history of substance use disorder, which is precisely what B.K. has, even though his own personal history carries none of that risk directly. The team's task is deciding whether his father's history should change the bridging plan itself, and if so, how — not simply noting it and prescribing exactly what would be offered to a patient without that family history.
At the intake consultation
His current level of impairment is real and severe enough that I don't think asking him to simply wait two to four weeks for the SSRI to work is a responsible plan — a short, clearly time-limited benzodiazepine course, with an explicit taper built in from day one rather than an open-ended prescription, is standard practice for anxious distress this disabling.
I want his father's history to actually change the plan, not just be documented and set aside — first-degree family history of alcohol use disorder is one of the more consistently replicated risk factors for developing dependence on other CNS depressants, including benzodiazepines, even in a patient with zero personal substance use history of his own.
That doesn't mean benzodiazepines are off the table entirely given how severe his current presentation is, but it argues for the shortest effective course, the lowest effective dose, no early refills, and a genuinely hard stop date agreed on before the first prescription is written — not the more open-ended bridging plan I'd be comfortable with in a patient without this family history.
A two-week course of lorazepam at 0.5mg twice daily as needed, dispensed with no refills and a specific, pre-set taper schedule, gives him real relief during the highest-impairment window without leaving room for the open-ended use pattern that family history risk is actually about. I'd also start hydroxyzine as a non-benzodiazepine option he can lean on afterward if anxious symptoms are still prominent once the benzodiazepine course ends and before the SSRI has fully taken effect.
Sertraline 50mg was started, alongside a two-week lorazepam course at 0.5mg twice daily as needed, dispensed with no refills and a specific pre-set taper schedule agreed upon before the first prescription was written, with hydroxyzine identified as the next step for any residual anxious symptoms after the benzodiazepine course ends.
The team's documentation was explicit that the bridging plan itself — its length, its lack of refills, and the built-in taper — was shaped directly by his father's history, not a generic anxious-distress protocol applied without regard to it; B.K. was included in that conversation directly rather than having the reasoning kept out of his own visit.